Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | CNR2 | P34972 | 2/20 | 0.54 |
| ▸ | FAAH | O00519 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3992125 | 1.00 | CNR1 (0.54) | CNR1ALDH1A1CNR2FAAHMAPT | |
| SCHEMBL2710460 | 0.98 | ALDH1A1 (0.53) | CNR1ALDH1A1CNR2HPGDTRPV1 | |
| SCHEMBL4619981 | 0.98 | ALDH1A1 (0.53) | CNR1ALDH1A1CNR2HPGDTRPV1 | |
| SCHEMBL1962550 | 0.93 | SPHK1 (0.53) | ALDH1A1MAPT | |
| SCHEMBL1101078 | 0.93 | SPHK1 (0.53) | ALDH1A1MAPT | |
| SCHEMBL27454783 | 0.93 | SPHK1 (0.53) | ALDH1A1MAPT | |
| SCHEMBL8574566 | 0.93 | SPHK1 (0.53) | ALDH1A1MAPT | |
| SCHEMBL1963079 | 0.93 | SPHK1 (0.53) | ALDH1A1MAPT | |
| SCHEMBL314278 | 0.93 | SPHK1 (0.53) | ALDH1A1MAPT | |
| SCHEMBL2232599 | 0.93 | SPHK1 (0.53) | ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110077239-A1 | GLYCINE RECEPTOR AGONISTS FOR THE TREATMENT OF PHANTOM PHENOMENA | EBERHARD-KARLS-UNIVERSITAET TUEBINGEN UNIVERSITAETSKLINIKUM (DE) | 2011-03-31 | — | — | US | claimed |
| WO-2009073788-A1 | COMPOSITIONS AND METHODS FOR TREATING MENOPAUSAL FEMALES | FIRESTONE LEIGH H (US) | 2009-06-11 | — | — | WO | claimed |
| WO-2001085158-A2 | ANANDAMIDE AND STRUCTURALLY RELATED LIPIDS AS VANILLOID RECEPTOR MODULATORS | FORSKARPATENT I SYD AB (SE) | 2001-11-15 | — | — | WO | claimed |
| EP-4618987-A1 | METHODS FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE BY MODULATING OR INHIBITING CANNABINOID RECEPTOR 1 | Joyboy The Igwe L.L.C. (US) | 2025-09-24 | — | — | EP | disclosed |
| WO-2024129891-A1 | METHODS FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE BY MODULATING OR INHIBITING CANNABINOID RECEPTOR 1 | JOYBOY THE IGWE L.L.C. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20190156919-A1 | DETERMINING RELATIONSHIPS BETWEEN RISKS FOR BIOLOGICAL CONDITIONS AND DYNAMIC ANALYTES | ARIVALE, INC. (US) | 2019-05-23 | — | — | US | disclosed |
| CN-109715613-A | Heterocyclic compound | 武田药品工业株式会社 | 2019-05-03 | — | — | CN | disclosed |
| EP-2569445-A1 | SCREENING ASSAYS BASED ON MAG AND/OR ABHD6 FOR SELECTING INSULIN SECRETION PROMOTING AGENTS | Val-Chlum, Limited Partnership (CA) | 2013-03-20 | — | — | EP | disclosed |
| US-8323680-B1 | Nutritional composition | NESTEC S.A. (CH) | 2012-12-04 | — | — | US | disclosed |
| US-20120252865-A1 | CARBAMATE DERIVATIVES IN PARTICULAR FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2012-10-04 | — | — | US | disclosed |
| EP-2408743-A1 | CARBAMATE DERIVATIVES IN PARTICULAR FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2012-01-25 | — | — | EP | disclosed |
| EP-1084098-A4 | INHIBITORS OF THE ANANDAMIDE TRANSPORTER AS ANALGESIC AGENTS | UNIV CONNECTICUT (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2004105699-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CANNABINOID AGENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004012727-A1 | COMPOSITIONS COMPRISING POLYSATURATED FATTY ACID (PUFAS) FOR THE CONTROL OF APPETITE AND BODY WEIGHT MANAGEMENT | ABBOTT LABORATORIES (US) | 2004-02-12 | — | — | WO | disclosed |
| EP-1307585-A1 | COMPOSITIONS AND METHODS FOR DETECTING AND QUANTIFYING COX-2 ACTIVITY AND 2-ARACHIDONYLGLYCEROL METABOLITES | VANDERBILT UNIVERSITY (US) | 2003-05-07 | — | — | EP | disclosed |
| US-20020064804-A1 | Compositions and methods for detecting and quantifying COX-2 activity and 2-arachidonylglycerol metabolites | VANDERBILT UNIVERSITY | 2002-05-30 | — | — | US | disclosed |
| WO-2002012549-A1 | COMPOSITIONS AND METHODS FOR DETECTING AND QUANTIFYING COX-2 ACTIVITY AND 2-ARACHIDONYLGLYCEROL METABOLITES | VANDERBILT UNIVERSITY (US) | 2002-02-14 | — | — | WO | disclosed |
| WO-2001085158-A2 | ANANDAMIDE AND STRUCTURALLY RELATED LIPIDS AS VANILLOID RECEPTOR MODULATORS | FORSKARPATENT I SYD AB (SE) | 2001-11-15 | — | — | WO | disclosed |
| EP-1084098-A1 | INHIBITORS OF THE ANANDAMIDE TRANSPORTER AS ANALGESIC AGENTS | Makriyannis, Alexandros (US) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999064389-A1 | INHIBITORS OF THE ANANDAMIDE TRANSPORTER AS ANALGESIC AGENTS | MAKRIYANNIS ALEXANDROS (US) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252865-A1 | CARBAMATE DERIVATIVES IN PARTICULAR FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | ACHE, CHRNA10, CHRNA5 | CNR1 7/4885ALDH1A1 818/4885CNR2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.